Market Chatter: Regal Takes Responsibility for Opthea Investment Losses

MT Newswires Live2025-04-02

Regal Investment Fund (ASX:RF1) Chief Investment Officer Phil King has taken responsibility for the firm's losses stemming from its investment in Opthea (ASX:OPT), the Australian Financial Review reported Wednesday, citing a letter to investors.

Opthea has said that its study of the combination of OPT-302 and aflibercept in patients with age-related macular degeneration failed to meet its primary endpoint, prompting it to terminate the study. It also added that there is "significant" doubt about its ability to continue as a going concern.

Regal, which held a 30% stake in Opthea, has written down the investment to zero, acknowledging the blow to investor returns across several funds, the report said.

The loss is expected to "significantly" affect the performance of Regal's long and short equity strategies for March, the report said.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2524177853?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-02 09:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524177853","market":"nz","top_or_hot":-1,"title":"Market Chatter: Regal Takes Responsibility for Opthea Investment Losses","media":"MT Newswires Live","content":"<html><body><p> Regal Investment Fund (ASX:RF1) Chief Investment Officer Phil King has taken responsibility for the firm's losses stemming from its investment in Opthea (ASX:OPT), the Australian Financial Review reported Wednesday, citing a letter to investors.</p><p>Opthea has said that its study of the combination of OPT-302 and aflibercept in patients with age-related macular degeneration failed to meet its primary endpoint, prompting it to terminate the study. It also added that there is \"significant\" doubt about its ability to continue as a going concern.</p><p>Regal, which held a 30% stake in Opthea, has written down the investment to zero, acknowledging the blow to investor returns across several funds, the report said.</p><p>The loss is expected to \"significantly\" affect the performance of Regal's long and short equity strategies for March, the report said.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Market Chatter: Regal Takes Responsibility for Opthea Investment Losses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarket Chatter: Regal Takes Responsibility for Opthea Investment Losses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-02 09:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Regal Investment Fund (ASX:RF1) Chief Investment Officer Phil King has taken responsibility for the firm's losses stemming from its investment in Opthea (ASX:OPT), the Australian Financial Review reported Wednesday, citing a letter to investors.</p><p>Opthea has said that its study of the combination of OPT-302 and aflibercept in patients with age-related macular degeneration failed to meet its primary endpoint, prompting it to terminate the study. It also added that there is \"significant\" doubt about its ability to continue as a going concern.</p><p>Regal, which held a 30% stake in Opthea, has written down the investment to zero, acknowledging the blow to investor returns across several funds, the report said.</p><p>The loss is expected to \"significantly\" affect the performance of Regal's long and short equity strategies for March, the report said.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OPT.AU","symbol_name":"OPTHEA LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2524177853","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524177853","pubTimestamp":1743557031,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Regal Investment Fund  Chief Investment Officer Phil King has taken responsibility for the firm's losses stemming from its investment in Opthea , the Australian Financial Review reported Wednesday, citing a letter to investors.Opthea has said that its study of the combination of OPT-302 and aflibercept in patients with age-related macular degeneration failed to meet its primary endpoint, prompting it to terminate the study. It also added that there is \"significant\" doubt about its ability to continue as a going concern.Regal, which held a 30% stake in Opthea, has written down the investment to zero, acknowledging the blow to investor returns across several funds, the report said.The loss is expected to \"significantly\" affect the performance of Regal's long and short equity strategies for March, the report said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OPT.AU":"OPTHEA LTD","BK4139":"生物科技","BK7067":"生物科技","RF1.AU":"REGAL INVESTMENT FUND","BK7508":"医药生物股"},"translate_title":"市场热议：富豪对Opthea投资损失承担责任","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OPT":1,"RF1.AU":0.9,"OPT.AU":1},"content_text":"Regal Investment Fund (ASX:RF1) Chief Investment Officer Phil King has taken responsibility for the firm's losses stemming from its investment in Opthea (ASX:OPT), the Australian Financial Review reported Wednesday, citing a letter to investors.Opthea has said that its study of the combination of OPT-302 and aflibercept in patients with age-related macular degeneration failed to meet its primary endpoint, prompting it to terminate the study. It also added that there is \"significant\" doubt about its ability to continue as a going concern.Regal, which held a 30% stake in Opthea, has written down the investment to zero, acknowledging the blow to investor returns across several funds, the report said.The loss is expected to \"significantly\" affect the performance of Regal's long and short equity strategies for March, the report said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2524177853","isCrawlerRequest":true}